Renalytix Plc (RTNXF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Renalytix Plc (RTNXF) stock?
Renalytix Plc (RTNXF) no longer trades on public markets. The figures below are historical and are not a current quote.
Market cap $22.6M is the value of all shares combined. Beta 2.07: the stock has moved about 107% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Renalytix Plc (RTNXF). Renalytix Plc is a healthcare company specializing in AI-enabled in vitro diagnostic solutions for kidney diseases. Market cap: $22.6M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for RTNXF: RTNXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RTNXF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
Renalytix Plc (RTNXF) Healthcare & Pipeline Overview
Renalytix Plc is a developer of AI-driven diagnostics for kidney disease, offering the KidneyIntelX platform that integrates biomarkers, genetics, and patient data to improve risk assessment and clinical decision-making. The company operates within the growing healthcare information services sector, focusing on early detection and personalized management of kidney conditions.
What Is the Investment Thesis for RTNXF?
The platform's ability to integrate diverse data points for personalized risk assessment in kidney disease offers a significant advantage in a market with substantial unmet needs. Key value drivers include the expansion of KidneyIntelX adoption among healthcare providers, successful execution of clinical partnerships, and potential for regulatory approvals and reimbursement coverage. However, investors may want to evaluate the company's current negative profitability, with a profit margin of -1461.6%, and the competitive landscape within the diagnostic sector. The company's high beta of 2.07 also indicates significant volatility. Successful commercialization and market penetration are crucial for Renalytix to achieve long-term sustainability and deliver value to shareholders.
Based on FMP financials and quantitative analysis
RTNXF Key Highlights
Renalytix Plc operates in the healthcare sector, specifically within medical and healthcare information services.
- The company's primary product, KidneyIntelX, is an AI-enabled diagnostic platform for kidney disease risk assessment.
- Renalytix has established partnerships with leading healthcare institutions, including Mount Sinai Health System and Atrium Health.
- The company's market capitalization is approximately $0.02 billion as of March 16, 2026.
- Renalytix has a negative P/E ratio of -0.33 and a gross margin of 6.8%.
Who Are RTNXF's Competitors?
RTNXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.4M | — |
| EMMLF OKYO Pharma Limited | $0.01 | 0.00% | $22.7M | — |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.1M | — |
| HDSLF HS GovTech Solutions Inc. | $0.39 | -0.39% | $21.1M | — |
| KBBTF Kubota Pharmaceutical Holdings Co., Ltd. | $0.96 | 0.00% | $24.1M | — |
| BEAT HeartBeam, Inc. | $0.40 | -2.14% | $22.3M | — |
| EUDA EUDA Health Holdings Limited | $13.12 | +0.15% | $24.5M | — |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RTNXF's Key Strengths?
Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Strategic partnerships with leading healthcare institutions.
- Focus on a high-need area (kidney disease).
- Potential for personalized medicine applications.
What Are RTNXF's Weaknesses?
Negative profitability and high operating expenses.
- Limited commercial traction to date.
- Reliance on partnerships for market access.
- OTC market listing may limit investor interest.
What Could Drive RTNXF Stock Higher?
Potential regulatory approvals for KidneyIntelX from FDA or other regulatory bodies.
- Expansion of partnerships with healthcare providers and pharmaceutical companies.
- Publication of clinical studies demonstrating the efficacy of KidneyIntelX.
- Increasing adoption of KidneyIntelX among healthcare providers.
What Are the Key Risks for RTNXF?
Financial-distress signal — its Altman Z-Score of -22.63 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Competition from established diagnostic companies and emerging players.
- Regulatory hurdles and changing reimbursement policies.
- Negative profitability and high operating expenses.
- Technological obsolescence.
- Economic downturn impacting healthcare spending.
What Are the Growth Opportunities for RTNXF?
- Expansion of KidneyIntelX Adoption: Renalytix has the opportunity to expand the adoption of its KidneyIntelX platform among healthcare providers and integrated delivery networks. By demonstrating the clinical and economic benefits of KidneyIntelX in improving patient outcomes and reducing healthcare costs, Renalytix can drive increased utilization and market penetration. The market for kidney disease diagnostics is estimated to be worth billions of dollars annually, providing a significant growth runway for Renalytix. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Renalytix can leverage strategic partnerships and collaborations to expand its reach and access new markets. By partnering with pharmaceutical companies, research institutions, and patient advocacy groups, Renalytix can accelerate the development and commercialization of its diagnostic solutions. These partnerships can also provide access to valuable data and insights, further enhancing the capabilities of the KidneyIntelX platform. Timeline: Ongoing.
- Regulatory Approvals and Reimbursement Coverage: Securing regulatory approvals and reimbursement coverage for KidneyIntelX is crucial for driving adoption and market access. Renalytix can pursue regulatory pathways such as FDA clearance or approval to validate the clinical utility of its platform. Obtaining favorable reimbursement coverage from payers will also be essential for ensuring that KidneyIntelX is accessible to patients and healthcare providers. Timeline: Upcoming.
- Geographic Expansion: Renalytix has the opportunity to expand its geographic footprint beyond the United States and into international markets. By targeting regions with a high prevalence of kidney disease and unmet diagnostic needs, Renalytix can tap into new revenue streams and diversify its customer base. This expansion may involve establishing partnerships with local distributors or setting up direct sales operations. Timeline: Upcoming.
- Development of New Diagnostic Solutions: Renalytix can leverage its AI and data analytics capabilities to develop new diagnostic solutions for other kidney-related conditions and diseases. By expanding its product portfolio, Renalytix can address a broader range of clinical needs and increase its market share. This may involve developing new biomarkers, algorithms, or diagnostic platforms. Timeline: Ongoing.
What Are RTNXF's Competitive Advantages?
- Proprietary AI-enabled KidneyIntelX platform.
- Strategic partnerships with leading healthcare institutions.
- Extensive data and biomarker library for algorithm training.
- First-mover advantage in the AI-driven kidney diagnostics market.
What Does RTNXF Do?
Renalytix Plc, formerly known as Renalytix AI plc, was incorporated in 2018 and is headquartered in New York City. The company is focused on developing artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Its primary product is KidneyIntelX, a diagnostic platform that utilizes an AI-enabled algorithm to combine data inputs such as blood-based biomarkers, inherited genetics, and patient data from electronic health records. This platform generates a patient-specific risk score, aiding in kidney disease diagnosis, prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix has established licensing agreements with institutions like Mount Sinai Health System, Joslin Diabetes Center, Inc., and Kantaro Biosciences LLC to develop and commercialize products related to AI-driven kidney disease diagnosis and antibody detection for SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix aims to transform kidney disease management by providing clinicians with actionable insights to improve patient outcomes and reduce healthcare costs.
What Products and Services Does RTNXF Offer?
- Develops AI-enabled in vitro diagnostic solutions for kidney diseases.
- Offers KidneyIntelX, a diagnostic platform using an AI algorithm.
- Combines blood-based biomarkers, genetics, and patient data for risk assessment.
- Provides insights for kidney disease diagnosis and prognosis.
- Supports clinical care and patient stratification for clinical trials.
- Aids in drug target discovery for kidney disease treatments.
How Does RTNXF Make Money?
- Generates revenue through the sale of KidneyIntelX diagnostic tests.
- Partners with healthcare providers and institutions for test utilization.
- Licenses its technology and data to pharmaceutical companies and research organizations.
- Forms strategic alliances to expand market reach and product offerings.
What Industry Does RTNXF Operate In?
Renalytix Plc operates within the healthcare information services industry, which is experiencing growth driven by the increasing adoption of AI and data analytics in healthcare. The market for kidney disease diagnostics is substantial, with a growing prevalence of chronic kidney disease (CKD) globally. The competitive landscape includes established diagnostic companies and emerging players focused on AI-driven solutions. Renalytix aims to differentiate itself through its integrated KidneyIntelX platform and strategic partnerships with healthcare providers. The industry is subject to regulatory oversight and reimbursement policies, which can impact market access and adoption.
Who Are RTNXF's Key Customers?
- Healthcare providers (nephrologists, primary care physicians).
- Hospitals and integrated delivery networks.
- Pharmaceutical companies conducting clinical trials.
- Research institutions studying kidney disease.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● Latest filing 619 days ago
- ● No analyst coverage
- ● This is an unknown, not an operating company
MoonshotScore History
Recorded daily since 2026-08-23 · 4 snapshots
| 2026-08-23 | 43 |
| 2026-08-24 | 43 |
| 2026-08-25 | 43 |
| 2026-08-26 | 43 |
What changed?
The score has stayed at 43.
Over the same 3 days the stock moved +0.0%.
Company Profile
Renalytix Plc operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO James R. McCullough. RTNXF has traded publicly since 2019.
Renalytix Plc Financial Trajectory
Renalytix Plc (RTNXF) reported $729K in revenue for Q2 FY2025, reflecting 39.7% growth compared to the prior quarter. The company recorded a net loss of $3.9M, with diluted EPS of $-0.04. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, RTNXF averaged $-0.06 in diluted EPS.
How Renalytix Plc Is Valued
Renalytix Plc carries a market capitalization of $22.6M, placing it in the micro-cap category.
Financial Health
Renalytix Plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -22.63 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Renalytix Plc has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 27.7% below estimates on average.
Forward Outlook
Wall Street analysts project Renalytix Plc revenue of about $61.8M for fiscal 2026, with EPS near $-0.22.
RTNXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Strategic partnerships with leading healthcare institutions.
- Focus on a high-need area (kidney disease).
- Potential for personalized medicine applications.
Bear Case
- Negative profitability and high operating expenses.
- Limited commercial traction to date.
- Reliance on partnerships for market access.
- OTC market listing may limit investor interest.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2025 | $729,000 | -$4M | -$0.04 |
| Q1 FY2025 | $522,000 | -$5M | -$0.04 |
| Q4 FY2024 | $586,000 | -$7M | -$0.07 |
| Q3 FY2024 | $532,618 | -$8M | -$0.08 |
Q2 FY2025 · filed 31 Dec 2024 · SEC EDGAR →
Based on FMP financials and quantitative analysis
RTNXF Latest News
-
Stocks That Hit 52-Week Highs On Monday
· Feb 10, 2020
Leadership: James R. McCullough
CEO
James R. McCullough serves as the CEO of Renalytix Plc, leading the company's efforts in developing and commercializing AI-enabled diagnostics for kidney disease. His background includes experience in the healthcare and technology sectors, with a focus on commercial strategy and market development. He has held leadership positions in various companies, driving growth and innovation in the diagnostic and biotechnology fields. McCullough's expertise spans across areas such as product development, sales, and marketing, contributing to his ability to steer Renalytix towards its strategic goals.
Track Record: Under James R. McCullough's leadership, Renalytix Plc has focused on expanding the adoption of its KidneyIntelX platform and establishing strategic partnerships with healthcare institutions. Key milestones include securing agreements with leading healthcare providers and advancing regulatory efforts to validate the clinical utility of KidneyIntelX. The company has also focused on expanding its data and biomarker library to enhance the capabilities of its AI-driven diagnostic solutions. However, the company is still loss-making.
RTNXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Renalytix Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, regulatory oversight, and investor protection compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information, liquidity, and regulatory scrutiny.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Lower trading volumes and liquidity.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement.
- Limited investor protection compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or press releases about the company.
- Established partnerships with reputable healthcare institutions.
- Proprietary AI-driven diagnostic platform (KidneyIntelX).
- Focus on a high-need area (kidney disease).
- Experienced management team with healthcare and technology expertise.
RTNXF Healthcare Stock FAQ
What happened to Renalytix Plc (RTNXF) stock?
Renalytix Plc (RTNXF) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy RTNXF shares?
No. RTNXF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for RTNXF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before RTNXF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Renalytix Plc. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Renalytix Plc do?
Renalytix Plc is a healthcare company specializing in the development and commercialization of AI-enabled in vitro diagnostic solutions for kidney diseases.
What are the main risks for RTNXF?
Renalytix Plc faces several risks, including competition from established diagnostic companies and emerging players in the AI-driven healthcare space. Regulatory hurdles and changing reimbursement policies could impact the adoption and market access of KidneyIntelX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market investments carry additional risks.